Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis

University of Alabama at Birmingham40 enrolled

Overview

The investigators are trying a combination vaginal product of higher dose metronidazole combined with miconazole to see if it is effective in treating vaginal trichomonas.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Trichomonas Vaginitis

Interventions

oral metronidazoleDRUG

2 gm oral once

neo penotran forteDRUG

neo penotran forte intravaginal twice a day for 7 days

neo penotran forte once a dayDRUG

neo penotran forte intravaginally once a day for 7 days

Eligibility

Sex: FEMALEMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * presence of trichomonas Exclusion Criteria: * pregnant or nursing * known immunodeficiency * allergy to study drugs * concurrent yeast infection * history of seizures or peripheral neuropathy * unwillingness to abstain from alcohol during treatment period and for 48 hrs after concurrent lithium * anticoagulation therapy, and abuse * patient expected to have menses within 8 days of enrollment

Locations (1)

Personal Health Clinic UAB

Birmingham, Alabama, United States

Outcomes

Primary Outcomes

Percentage of Participants Cured of Vaginal Trichmonas

percentage of participants achieving microbiological cure of trichomonas

Time frame: day 12-15

Secondary Outcomes

Tolerability of the Study Product as Measured by Participant Self-report

Number of participants with any side effects

Time frame: day 12-15 day 30-35

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.